{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:40Z","timestamp":1786997860074,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.06.080","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T10:16:50Z","timestamp":1564222610000},"page":"4823-4829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-7248","authenticated-orcid":false,"given":"Bruce L.","family":"Innis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Berlanda Scorza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastazia","family":"Older Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane J.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niteen","family":"Wairagkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2019.06.080_b0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2019.06.080_b0010","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2019.06.080_b0015","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1016\/j.vaccine.2019.06.053","article-title":"Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations","volume":"37","author":"Innis","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.080_b0020","unstructured":"World Health Organization. WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines. May 2017. ISBN 978-92-4-151246-6."},{"key":"#cr-split#-10.1016\/j.vaccine.2019.06.080_b0025.1","unstructured":"The Bill and Melinda Gates Foundation. Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development. 2018, June 22"},{"key":"#cr-split#-10.1016\/j.vaccine.2019.06.080_b0025.2","unstructured":"Accessed 2018, November 8. <https:\/\/gcgh.grandchallenges.org\/challenge\/ending-pandemic-threat-grand-challenge-universal-influenza-vaccine-development>."},{"issue":"4","key":"10.1016\/j.vaccine.2019.06.080_b0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1172\/JCI101633","article-title":"Protective effect of vaccination against induced influenza A","volume":"24","author":"Francis","year":"1945","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.vaccine.2019.06.080_b0035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI101634","article-title":"Protective effect of vaccination against induced influenza B","volume":"24","author":"Salk","year":"1945","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.vaccine.2019.06.080_b0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jmv.1890030303","article-title":"Attenuated influenza produced by experimental intranasal inoculation","volume":"3","author":"Little","year":"1979","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2019.06.080_b0045","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/aje\/kwm375","article-title":"Time lines of infection and disease in human influenza: a review of volunteer challenge studies","volume":"167","author":"Carrat","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.06.080_b0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fcimb.2019.00107","article-title":"The future of flu: a review of the human challenge model and systems biology for advancement of influenza vaccinology","volume":"9","author":"Sherman","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2019.06.080_b0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijid.2016.05.013","article-title":"Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies","volume":"49","author":"Balasingam","year":"2016","journal-title":"Int J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2019.06.080_b0060","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/cid\/ciu078","article-title":"An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution","volume":"58","author":"Waddington","year":"2014","journal-title":"Clin Infect Dis."},{"issue":"11","key":"10.1016\/j.vaccine.2019.06.080_b0065","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.080_b0070","unstructured":"Shah K KJ, Lyerly AD, Lynch HF, et al. Ethical considerations for zika virus human challenge trials. 2017; <https:\/\/www.niaid.nih.gov\/sites\/default\/files\/EthicsZikaHumanChallengeStudiesReport2017.pdf>."},{"issue":"5","key":"10.1016\/j.vaccine.2019.06.080_b0075","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/cid\/ciu924","article-title":"Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study","volume":"60","author":"Memoli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.080_b0080","unstructured":"Centers for Disease Control and Prevention. Dual Use Research of Concern and Bird Flu: Questions & Answers. 2017. Accessed November 18, 2018. < https:\/\/www.cdc.gov\/flu\/avianflu\/avian-durc-qa.htm>."},{"key":"10.1016\/j.vaccine.2019.06.080_b0085","unstructured":"Recommended Policy Guidance for Departmental Development of Review Mechanisms for Potential Pandemic Pathogen Care and Oversight (P3CO). 2017. Accessed November 8, 2018. <https:\/\/www.phe.gov\/s3\/dualuse\/Documents\/P3CO-FinalGuidanceStatement.pdf>."},{"key":"10.1016\/j.vaccine.2019.06.080_b0090","unstructured":"Centers for Disease Control and Prevention. Influenza Risk Assessment Tool (IRAT). 2016. Accessed November 8, 2018. <https:\/\/www.cdc.gov\/flu\/pandemic-resources\/national-strategy\/risk-assessment.htm>."},{"key":"10.1016\/j.vaccine.2019.06.080_b0095","unstructured":"World Health Organization. Tool for Influenza Pandemic Risk Assessment (TIPRA). 2016. Accessed November 12, 2018. <https:\/\/www.who.int\/influenza\/areas_of_work\/human_animal_interface\/tipra\/en\/>."},{"key":"10.1016\/j.vaccine.2019.06.080_b0100","unstructured":"World Health Organization. Human Challenge Trials for Vaccine Development: regulatory considerations. 2016. Accessed November 12, 2018. <https:\/\/www.who.int\/biologicals\/expert_committee\/Human_challenge_Trials_IK_final.pdf>."},{"issue":"3","key":"10.1016\/j.vaccine.2019.06.080_b0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/CVI.00613-15","article-title":"Standardization of hemagglutination inhibition assay for influenza serology allows for high reproducibility between laboratories","volume":"23","author":"Zacour","year":"2016","journal-title":"Clin Vaccine Immunol."},{"issue":"27","key":"10.1016\/j.vaccine.2019.06.080_b0110","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1016\/j.vaccine.2012.02.077","article-title":"Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach","volume":"30","author":"Wagner","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.080_b0115","unstructured":"CONCISE: Consortium for the Standardization of Influenza Seroepidemiology. Accessed November 15, 2018. <https:\/\/consise.tghn.org>."},{"key":"10.1016\/j.vaccine.2019.06.080_b0120","unstructured":"The FLUCOP Project. 2015. Accessed November 15, 2018. <http:\/\/www.flucop.eu>."},{"key":"10.1016\/j.vaccine.2019.06.080_b0125","unstructured":"UNISEC: Universal Influenza Vaccines Secured. 2015. Accessed November 15, 2019. <https:\/\/www.unisecconsortium.eu>."},{"key":"10.1016\/j.vaccine.2019.06.080_b0130","unstructured":"The ISARIC-WHO Data Tools for Severe Acute Respiratory Infections. Accessed November 15, 2018. <https:\/\/isaric.tghn.org\/protocols\/severe-acute-respiratory-infection-data-tools\/>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:23Z","timestamp":1759401263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19308576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":27,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19308576"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}